Our History
BRIM Founded
2014
Series A (USD 4M)
BRM132 In-licensed
2015
Series B (USD 26M)
PDSP Platform In-licensed
2016
BRM421 U.S. IND Approval
2017
BRM421 U.S. FIH Study
BRM132 U.S. IND Approval
2018
Series C (USD 6M)
2019
BRM421 U.S. SIH Study Completed
BRM521 Pre-clinical Studies On-going
2020
BRM421 CN Right Licensed to CGP
Subsidiary Ascendo Biotech Formed (raised USD 12M)